A Double-Blind, Randomized, 12-Month, Placebo-Controlled, Parallel Group, Fixed-Dose Study to Evaluate the Efficacy and Safety of AVE5530 25mg/Day and AVE5530 50 mg/Day in Patients With Primary Hypercholesterolemia.

Trial Profile

A Double-Blind, Randomized, 12-Month, Placebo-Controlled, Parallel Group, Fixed-Dose Study to Evaluate the Efficacy and Safety of AVE5530 25mg/Day and AVE5530 50 mg/Day in Patients With Primary Hypercholesterolemia.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 17 May 2016

At a glance

  • Drugs Canosimibe (Primary)
  • Indications Hypercholesterolaemia
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 22 Jul 2009 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 20 May 2009 Planned end date changed from 1 Mar 2010 to 1 Jun 2009 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top